Company intelligence / Profile preview

Acelyrin

Agoura Hills, California, United Statesacelyrin.com ↗

Ownership: Public · SLRN
Employees: ~83
Development stage: Phase 3

Overview

Acelyrin's lead product candidate lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED)[5]. The company previously worked on izokibep for immune diseases but discontinued development and is seeking a partner to advance that program[7].

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

izokibep

Phase 2b/3

Indications: Uveitis

2 more assets in the full pipeline.

Request access →

Partnerships

Proposed merger with Alumis (scheduled for stockholder vote on May 13, 2025)[1]

Financials

Market cap: $229.2M
Total revenue: $0
Enterprise value: $-175.5M

Beyond the preview

Go deeper on Acelyrin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acelyrin.

Explore the full profile